HPS Pharmacies wish to advise that Pfizer is changing the formulation of Ibrance® (palbociclib).
From January 2022, all three strengths will transition from the current capsule formulation the new tablet form. There is no change to the active ingredient, available strengths, dosing schedule, or monitoring requirements.
Key benefits offered by the new tablet formulation include:
- Tablets may be taken with or without food
- Blister pack may assist patients to keep track of their treatment cycles; and
- Minimised dietary concerns (tablets are free of lactose, gluten, and gelatin).
For further information, consult the updated Product Information.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates